[Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
作者信息
Saitta A, Bonaiuto M, Lanzafame F, Mileto A, Pernice F, Cinquegrani M, Mazza G, Micali G, Pangallo A, Fodale P
出版信息
Clin Ter. 1988 Mar 15;124(5):373-81.
PMID:2974348
Abstract
摘要
相似文献
1
[Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
Clin Ter. 1988 Mar 15;124(5):373-81.
2
3
[Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].用苯扎贝特对原发性高脂蛋白血症进行有效的长期治疗
Schweiz Med Wochenschr. 1985 Jun 29;115(26):907-11.
4
[Effect of bezafibrate therapy on serum and lipoprotein lipids].
Orv Hetil. 1986 Oct 5;127(40):2425-8, 2431.
5
Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
Horm Metab Res. 1986 Sep;18(9):654-5. doi: 10.1055/s-2007-1012398.
6
Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia.
Atherosclerosis. 1987 Feb;63(2-3):203-9. doi: 10.1016/0021-9150(87)90122-5.
7
[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].[苯扎贝特对各型高脂蛋白血症的治疗效果]
Schweiz Med Wochenschr. 1980 Dec 6;110(49):1875-7.
8
9
Zotero 插件